We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
-40.93%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$94.6M
AUM Growth
-$48.9M
(-34%)
Cap. Flow
+$28M
Cap. Flow
% of AUM
29.63%
Top 10 Holdings %
Top 10 Hldgs %
59.92%
Holding
33
New
10
Increased
9
Reduced
7
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$14.6M |
| 2 |
STML
Stemline Therapeutics, Inc.
STML
|
+$5.75M |
| 3 |
Gyre Therapeutics
GYRE
|
+$4.36M |
| 4 |
BXRX
Baudax Bio, Inc. Common Stock
BXRX
|
+$4.12M |
| 5 |
CDTX
Cidara Therapeutics
CDTX
|
+$3.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$4.83M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$3.96M |
| 3 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$3.58M |
| 4 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
+$2.76M |
| 5 |
Aptevo Therapeutics
APVO
|
+$2.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rigel Pharmaceuticals
RIGL
$681M
| $16K | 0.02% |
+1,000
| New | +$21.3K |
|
27
Adicet Bio
ACET
$85.2M
| – | – |
-730
| Closed | -$122K |
|
|
28
Aptevo Therapeutics
APVO
$5.12M
| – | – |
-1
| Closed | -$2.73M |
|
29
SCYNEXIS
SCYX
$48.1M
| – | – |
-7,617
| Closed | -$555K |
|
|
ACER
30
DELISTED
Acer Therapeutics Inc
ACER
| – | – |
-20,000
| Closed | -$80K |
|
|
SBBP
31
DELISTED
Strongbridge Biopharma plc.
SBBP
| – | – |
-431,853
| Closed | -$903K |
|
|
NVLN
32
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| – | – |
-3,909,207
| Closed | -$2.76M |
|
Similar funds
ER
FDDB
VM
SCM
CWM
EWM
RA
TAM
Stonepine Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Stonepine Capital Management held 33 positions worth $94.6M, down 34% from $143M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Stonepine Capital Management deployed $28M of net new capital in Q1 2020, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Ligand Pharmaceuticals: 257,953 shares worth $11.7M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.
On the sell side, the largest reduction was Adamas Pharmaceuticals, an estimated $4.83M trimmed.
- Stonepine Capital Management's largest Q1 2020 buy was Ligand Pharmaceuticals: 257,953 shares worth $11.7M.
- Stonepine Capital Management added most to Gyre Therapeutics in Q1 2020, an estimated $4.36M increase.
- Stonepine Capital Management's biggest Q1 2020 reduction was Adamas Pharmaceuticals, cutting an estimated $4.83M.
- Stonepine Capital Management fully exited Novelion Therapeutics Inc. Common Shares in Q1 2020, selling an estimated $2.76M.
- Stonepine Capital Management's ten largest holdings make up 60% of its $94.6M portfolio in Q1 2020.
- Stonepine Capital Management opened 10 new positions and closed 7 in Q1 2020.
- Stonepine Capital Management's portfolio value fell 34% quarter-over-quarter to $94.6M.
Based on Stonepine Capital Management's 13F filing for Q1 2020, filed 14 May 2020.